Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.

TQB3602 is well tolerated, with a favorable neurotoxicity profile, and has shown preliminary efficacy in patients with RRMM. The anticipated therapeutic dose was 6 mg and was adopted for an ongoing dose-expansion phase.